RxDoctor Payments Data

Wendy Rissinger, MD

Family Medicine · Herndon, PANPI 1184727190

Payments from drug & device makers

$495in general payments, 2019–2025

Across 27 payments — averaging $18.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$185
  • Lilly USA, LLC$107
  • GSK$82
  • AbbVie$69
  • Phathom Pharmaceuticals, Inc.$28
  • Merck$22

What the payments were for

  • Food & beverage$495100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk11$185
Lilly USA, LLC6$107
GSK4$82
AbbVie3$69
Phathom Pharmaceuticals, Inc.2$28
Merck1$22

How this compares

$495 in reported general payments places this provider in the 60th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$130,968
Medicare patients
172
Services billed
2,002

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin69$74,407
EliquisApixaban76$73,598
TrulicityDulaglutide67$64,719
MounjaroTirzepatide29$29,695
XareltoRivaroxaban26$26,648
OzempicSemaglutide16$20,035
JanuviaSitagliptin Phosphate27$18,373
LinzessLinaclotide16$11,633
Warfarin Sodium791$9,642
Enoxaparin Sodium58$9,404
Lantus SolostarInsulin Glargine,hum.Rec.Anlog54$8,978
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$8,754
MyrbetriqMirabegron12$5,242
Incruse ElliptaUmeclidinium Bromide13$4,556
Atorvastatin Calcium336$4,342

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$107$94,41396 claims
Novo NordiskOzempic$185$20,03516 claims
MerckJanuvia$22$18,37327 claims
AbbVieLinzess$69$11,63316 claims
GSKIncruse Ellipta$82$4,55613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Herndon

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →